-- 多伦多证券交易所周四录得六天以来的首个上涨交易日,收复了此前五个交易日共计630点的跌幅,涨幅超过30点,这主要得益于逢低买盘以及加拿大经济第一季度的反弹。 S&P/TSX综合指数上涨645.94点,涨幅1.9%,收于33,964.33点。多数板块上涨,其中基本金属板块领涨,涨幅接近3%,即便金价下跌。能源板块也上涨0.8%,尽管油价走低。 电池金属指数下跌2.7%。 关于经济,丰业银行资本市场经济主管德里克·霍尔特指出,加拿大经济在第一季度出现反弹,“可能略好于”加拿大央行昨日发布的预测。霍尔特表示,“不过,这些数据只是回顾性的,除了驳斥年初以来对经济基本面更为悲观的普遍看法之外,并不能说明太多问题。”霍尔特指出,经季节性调整后,加拿大经济环比增长0.17%,屏幕上四舍五入后为0.2%。加拿大统计局对3月份的初步预测是GDP持平,但未提供任何细节。霍尔特补充说,这意味着第一季度GDP环比经季节性调整后的年化增长率(SAAR)为1.7%,较第四季度0.3%的环比收缩有所反弹,“但这两个数据旁边都有一个星号”。 霍尔特表示,这个星号表明我们使用的是月度生产性GDP数据。他还补充说,加拿大央行和华尔街更关注更全面的季度GDP数据,这些数据还会考虑经济活动的产生方式,例如库存投资的波动。 霍尔特表示,这种差异可能相当显著。第四季度按支出计算的GDP环比下降0.6%(经季节性调整后),原因是库存消耗导致GDP增长受到4.2个百分点的加权拖累。剔除库存影响后,最终国内需求环比增长2.3%(经季节性调整后)。霍尔特补充道:“我们尚未掌握第一季度完整的库存和贸易情况,因此仍存在一定的追踪风险。” 霍尔特引用了一张图表,展示了2月份GDP增长的驱动因素。他表示,制造业表现突出,而其他行业则呈现出小幅增长和拖累并存的局面。他认为,部分拖累因素与天气有关,例如建筑业,以及一些休闲娱乐类行业。 因此,霍尔特认为,尽管GDP有所反弹,但其增速可能超过了经济供给侧的增长,这或许会在我们获得完整的第一季度GDP数据后,转化为产出缺口的缩小。 周四午后,大宗商品方面,由于美元走软,黄金价格上涨。此前公布的数据显示,美国一项关键通胀指标上月上升,而第一季度国内生产总值增幅低于预期。6月交割的黄金期货价格上涨71.30美元,至每盎司4632.80美元,仍维持在过去一个月200美元的区间内。 但西德克萨斯中质原油价格收跌,从隔夜亚洲交易时段触及的四年高位回落。此前有报道称,美国可能结束与伊朗的停火协议,而有史以来最大的供应冲击对依赖波斯湾原油供应的非洲大陆打击尤为严重,这些原油目前被封闭的霍尔木兹海峡阻隔。 6 月份交割的 WTI 原油期货价格下跌 1.81 美元,收于每桶 105.07 美元,此前隔夜一度触及每桶 110.93 美元;而 6 月份交割的布伦特原油期货价格下跌 4.12 美元,收于每桶 113.91 美元,此前隔夜一度触及每桶 126.34 美元,为 2022 年以来的最高水平。
Related Articles
Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.
ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue
ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.
Research Alert: Gddy: Strong Profitability Metrics Offset By Continued Revenue Headwinds
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GDDY posted Q1 2026 revenue of $1.2B (+6%), in line with consensus, with EPS of $1.60 beating estimates of $1.52 despite booking deceleration to +2.7% from +5% in Q4. A&C segment growth of +11.6% to $498M showed resilience but continued moderating, while Core Platform remained sluggish at +2.8%. We view booking weakness as concerning given competitive pressures and small business spending constraints that raise questions about growth sustainability. Management reaffirmed 2026 revenue guidance of $5.195B-$5.275B (~6% growth), reflecting limited visibility into booking improvement. However, we see encouraging AI monetization signs with ARPU growth of +9.3% to $246 and Airo AI Builder achieving multi-million dollar annualized bookings within weeks of beta launch. We believe GDDY's impressive margin expansion with NEBITDA margins reaching 32.6% (+210 bps) demonstrates operational discipline, though sustaining A&C growth above 10% remains critical for investor confidence.